Shattuck Labs, Inc.
Close on Oct 19, 2026
- Market cap
- $696.91M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | – | $-0.12 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | – | $-0.13 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | Before market open | – | $-0.12 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | – | $-0.24 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 1, 2025 | During market hours | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | Before market open | – | $-0.37 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | $3.00M | $-0.33 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | During market hours | – | – | – |
Press releases
Announcements Shattuck Labs filed with the SEC
Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Shattuck Labs Announces Phase 1 Results for SL-325
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Phase 1 Clinical Data of SL-325, a
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K/A
Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
Agreement terminated · Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
S hattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of
Regulation FD disclosure · EX-99.1 to Form 8-K
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
Regulation FD disclosure · EX-99.1 to Form 8-K
Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K